Muston D, Hettle R, Monberg M, McLaurin KK, et al. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol 2020 Sep 18. pii: S0090-8258(20)33814.
PMID: 32951894